Targeting VEGF and VEGFR signaling in a tumor has been considered as a promising and attractive therapeutic strategy, and several approaches have been investigated, including the use of antibodies against VEGF receptors [32, 33], small tyrosine kinase inhibitors [34–36], and soluble receptors that trap lymph/angiogenic factors [37]. The gene discussed is VEGFA; the disease is neoplasm.